105 related articles for article (PubMed ID: 1724917)
1. Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.
Stephens RW; Tapiovaara H; Reisberg T; Bizik J; Vaheri A
Cell Regul; 1991 Dec; 2(12):1057-65. PubMed ID: 1724917
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.
Bizik J; Lizonová A; Stephens RW; Grófová M; Vaheri A
Cell Regul; 1990 Nov; 1(12):895-905. PubMed ID: 1712633
[TBL] [Abstract][Full Text] [Related]
3. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
Stephens RW; Pöllänen J; Tapiovaara H; Leung KC; Sim PS; Salonen EM; Rønne E; Behrendt N; Danø K; Vaheri A
J Cell Biol; 1989 May; 108(5):1987-95. PubMed ID: 2523891
[TBL] [Abstract][Full Text] [Related]
4. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
[TBL] [Abstract][Full Text] [Related]
5. Persistence of plasmin-mediated pro-urokinase activation on the surface of human monocytoid leukemia cells in vitro.
Tapiovaara H; Stephens RW; Vaheri A
Int J Cancer; 1993 Feb; 53(3):499-505. PubMed ID: 8428801
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
[TBL] [Abstract][Full Text] [Related]
7. Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor.
Mars WM; Kim TH; Stolz DB; Liu ML; Michalopoulos GK
Cancer Res; 1996 Jun; 56(12):2837-43. PubMed ID: 8665523
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional characterization of the inhibition of urokinase by alpha 2-macroglobulin.
Straight DL; Hassett MA; McKee PA
Biochemistry; 1985 Jul; 24(15):3902-7. PubMed ID: 2413880
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages.
Saksela O; Hovi T; Vaheri A
J Cell Physiol; 1985 Jan; 122(1):125-32. PubMed ID: 2578131
[TBL] [Abstract][Full Text] [Related]
10. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.
Kirchheimer JC; Wojta J; Christ G; Binder BR
Proc Natl Acad Sci U S A; 1989 Jul; 86(14):5424-8. PubMed ID: 2501786
[TBL] [Abstract][Full Text] [Related]
11. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices.
Kroon ME; Koolwijk P; van Goor H; Weidle UH; Collen A; van der Pluijm G; van Hinsbergh VW
Am J Pathol; 1999 Jun; 154(6):1731-42. PubMed ID: 10362798
[TBL] [Abstract][Full Text] [Related]
12. A T-cell-related proteinase expressed by T-lymphoma cells activates their endogenous pro-urokinase.
Brunner G; Vettel U; Jobstmann S; Kramer MD; Schirrmacher V
Blood; 1992 Apr; 79(8):2099-106. PubMed ID: 1562736
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
Sitter T; Toet K; Quax P; Kooistra T
Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
[TBL] [Abstract][Full Text] [Related]
14. The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats.
van der Kaaden ME; Rijken DC; Kruijt JK; van Berkel TJ; Kuiper J
Thromb Haemost; 1997 Apr; 77(4):710-7. PubMed ID: 9134648
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid potentiates phorbol ester-mediated induction of urokinase and plasminogen activator inhibitor type 2 in human myeloid leukemic cell lines.
Schuster WA; Medcalf RL; Kruithof EK
Endocrinology; 1993 Oct; 133(4):1724-30. PubMed ID: 8404615
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
[TBL] [Abstract][Full Text] [Related]
17. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
Gyetko MR; Webb AC; Sitrin RG
J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
[TBL] [Abstract][Full Text] [Related]
18. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
[TBL] [Abstract][Full Text] [Related]
19. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A; Webber MM
Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
